FIELD: biotechnology.
SUBSTANCE: invention relates to chimeric proteins for inducing cell apoptosis, and can be used in cell therapy. Disclosed is a chimeric protein which is characterized by a specific formula and comprises a first heterodimerisation domain, a second heterodimerisation domain and caspase domain, wherein in the presence of a chemical dimerisation inducer (CID) of a pair of identical chimeric proteins, reacts so that the first heterodimerisation domain of one chimeric protein is heterodimerised with the second heterodimerisation domain of another chimeric protein, causing homodimerisation and activation of two caspase domains. At that, one heterodimerisation domain from said first and second heterodimerisation domains comprises a FK506 binding protein (FKBP), and the other heterodimerisation domain of said first and second heterodimerisation domains comprises the FRB mTOR domain and wherein the CID is rapamycin or rapamycin analogue.
EFFECT: invention provides effective induction of apoptosis in a cell containing said chimeric protein when exposed to rapamycin or its analogue.
26 cl, 4 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| SIGNAL SYSTEM | 2015 |
|
RU2731638C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF ENDONUCLEASE CBLB | 2018 |
|
RU2779097C2 |
| NEW ANTI-IL13 ANTIBODIES AND USE THEREOF | 2020 |
|
RU2752833C1 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| ANTIBODIES AGAINST GUCY2c AND THEIR USE | 2019 |
|
RU2812113C2 |
| INDUCED CASPASES AND METHODS FOR THEIR USE | 2017 |
|
RU2757058C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
